Supplementary Online Content

Berlinberg EJ, Gonzales JA, Doan T, Acharya NR. Association between noninfectious uveitis and psychological stress. *JAMA Ophthalmol*. Published online December 6, 2018. doi:10.1001/jamaophthalmol.2018.5893

eTable. Demographic and Clinical Characteristics of Uveitis Group

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Demographic and Clinical Characteristics of Uveitis Group

Variable	Recently Active Uveitis N (%)	Controlled Uveitis N (%)	*P*-value
Female	24 (60%)	26 (65%)	.82[a]
Mean Age (SD)	43.4 (18.6)	45.4 (16.1)	.60[b]
Race/Ethnicity			.68[a]
White	21 (52 %)	23 (58%)	
Black	4 (10%)	3 (8%)	
Asian	7 (18%)	10 (25%)	
Hispanic	3 (8%)	3 (8%)	
Other	1 (2%)	0 (0%)	
Multiracial	4 (10%)	1 (2%)	
Current smoker	2 (5%)	2 (5%)	.85[a]
Median Household Income in Dollars (IQR)	86,661.50 (56,646.50 – 129,108.00)	78,301.00 (68,869.00 – 119,281.00)	.90[c]
Marital Status			.29[a]
Single	18 (45%)	13 (32%)	
Married	21 (52%)	22 (55%)	
Divorced	0 (0%)	3 (8%)	
Widowed	1 (2%)	1 (2%)	
Separated	0 (0%)	1 (2%)	
Living Situation			.78[a]
Alone	4 (10%)	7 (18%)	
With Family	29 (72%)	26 (65%)	
With Friends	2 (5%)	3 (8%)	
With Roommates	5 (12%)	4 (10%)	
Education			.27[a]
Less than High School	1 (2%)	0 (0%)	
High School	3 (8%)	3 (8%)	
Some College	13 (32%)	6 (15%)	
Bachelor's Degree	12 (30%)	15 (38%)	
Professional or Graduate Degree	11 (28%)	16 (15%)	
Mean Drinks per Week (SD)	2 (3)	2 (3)	.89[b]
Have Dependents	11 (28%)	12 (30%)	>.99[a]
Comorbid Conditions			
Heart disease	3 (8%)	1 (2%)	.62[a]
Cancer	5 (12%)	4 (10%)	>.99[a]
Depression	12 (30%)	4 (10%)	.05[a]
Anxiety	9 (22%)	6 (15%)	.57[a]
Hypertension	7 (18%)	3 (8%)	.31[a]
Diabetes	3 (8%)	3 (8%)	>.99[a]
Systemic Autoimmune (Other than Diabetes)	16 (40%)	20 (50%)	.50[a]

Variable	Recently Active Uveitis N (%)	Controlled Uveitis N (%)	*P*-value
Median Number of All Other Comorbid Conditions (Excluding Systemic Autoimmune) (IQR)	0 (0 - 1)	0.5 (0 - 2)	.08[c]
Work Status			.66[a]
Unemployed	4 (10%)	2 (5%)	
Full Time	21 (52%)	24 (60%)	
Part Time	5 (12%)	4 (10%)	
Retired	7 (18%)	7 (18%)	
Homemaker	0 (0%)	2 (5%)	
Other	3 (8%)	1 (2%)	
VAS Pain (0-10) mean (SD)	20.1 (26.1)	12.4 (20.2)	.14[b]
Median converted logMAR Vision in the better seeing eye (IQR)	0.14 (0 - 0.39)	0 (0 - 0.1)	.003[c]
Anatomical Location			.16[a]
Anterior	23 (58%)	18 (45%)	
Intermediate	2 (2%)	5 (12%)	
Anterior + Intermediate	3 (8%)	7 (18%)	
Posterior	6 (15%)	2 (5%)	
Panuveitis	7 (18%)	8 (20%)	
Bilateral Disease	35 (88%)	28 (70%)	.10[a]
Uveitis Diagnosis			.09[a]
Undifferentiated	20 (50%)	11 (28%)	
Retinal vasculitis	2 (5%)	2 (5%)	
Serpiginous choroiditis	0 (0%)	1 (2%)	
Multifocal choroiditis with panuveitis	2 (5%)	2 (5%)	
Birdshot retinochoroidopathy	0 (0%)	2 (5%)	
Pars planitis	3 (8%)	1 (2%)	
Behçet's disease	0 (0%)	2 (5%)	
Sarcoidosis	3 (8%)	4 (10%)	
Multiple sclerosis	0 (0%)	2 (5%)	
Juvenile idiopathic arthritis	1 (2%)	1 (2%)	
Seronegative spondyloarthropathy	2 (5%)	8 (20%)	
Inflammatory bowel disease	0 (0%)	1 (2%)	
HLA-B27 positive, no reported joint involvement	0 (0%)	3 (8%)	
Vogt-Koyanagi-Harada disease	0 (0%)	1 (2%)	
Other	4 (10%)	2 (5%)	
Median years duration of disease (IQR)	5.5 (1 - 12)	6 (2 - 14)	.30[c]
Diagnosed Systemic Disease	16 (40%)	23 (58%)	.18[a]
Any corticosteroid use	33 (82%)	17 (42%)	<.001[a]
Current Immunomodulatory Therapy	18 (45%)	20 (50%)	.82[a]
Number of eye medications (IQR)	1.5 (1 - 3.5)	1 (0 - 3)	.17[c]
Number of previous injections (IQR)	0 (0 - 1.5)	0 (0 - 0)	.01[c]

a. Fisher's exact test
b. Student's t-test
c. Mann-Whitney U test